Table 1. Demographic and clinical characteristics of patients with systemic sclerosis (n=50).
| Sociodemographic and clinical characteristics | ||
|---|---|---|
| Age (years) median (IQR) | 52.0 (37.7–58.2) | |
| Female n (%) | 46 (92%) | |
| Disease duration (years) median (IQR) | 7.0 (4.0–13.0) | |
| Clinical subset n (%) | ||
| Limited cutaneous | 30 (60%) | |
| Diffuse cutaneous | 18 (36%) | |
| Sine scleroderma | 2 (4%) | |
| Overlap | 6 (12%) | |
| Clinical manifestations n (%) | ||
| Raynaud's phenomenon | 49 (98%) | |
| Interstitial lung disease | 34 (68%) | |
| Esophageal dysmotility | 39 (78%) | |
| Digital ulcers | 26 (52%) | |
| Myopathy | 5 (10%) | |
| Pulmonary arterial hypertension | 5 (10%) | |
| Arthritis | 34 (68%) | |
| Telangiectasia | 15 (30%) | |
| Calcinosis | 5 (10%) | |
| PSQI mean (±SD) | 9.63 (±4.88) | |
| ESS-BR mean (±SD) | 6.62 (±5.23) | |
| SHAQ mean (±SD) | 1.42 (±0.73) | |
| SF-12 PCS mean (±SD) | 35.36 (±10.28) | |
| SF-12 MCS mean (±SD) | 42.60 (±12.38) | |
ESS-BR: Epworth Sleepiness Scale–Portuguese version; IQR: interquartile range; MCS: mental component summary; PCS: physical component summary; PSQI: Pittsburgh Sleep Quality Index; SD: standard deviation; SF-12: 12-item short-form health survey; SHAQ: scleroderma health assessment questionnaire.